Skip to content
Screener

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$534M+11.7%
Gilead Sciences logo
Gilead SciencesGILD
$98M+5.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.19M-7.6%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$360K-64.1%
Immunome logo
ImmunomeIMNM
$603K-1.3%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$270K-10.6%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.55B+150%
Enterprise value$4.54B+142%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Celcuity’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-023180
Line item2026 / Three Months Ended March 31,2025 / Three Months Ended March 31,
Cash flows from operating activities:
Net loss$(52,841)$(36,997)
Adjustments to reconcile net loss to net cash and cash equivalents used in operations:
Depreciation4737
Stock-based compensation5,3252,444
Amortization of debt issuance costs and discount1,252551
Payment-in-kind interest325249
Non-cash interest income(883)(946)

Item 1. Financial Statements (unaudited) ITEM

FAQ

What is Celcuity's D&A?
Celcuity (CELC) reported D&A of $47K in Q1 2026.
How has Celcuity's D&A changed year-over-year?
Celcuity's D&A increased by 27.0% year-over-year, from $37K to $47K.
What is the long-term trend for Celcuity's D&A?
Over 4 years (2021 to 2025), Celcuity's D&A has grown at a -13.9% compound annual growth rate (CAGR), from $303.24K to $167K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Celcuity's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude